Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1411 to 1420 of 2733 total matches.
Extended-Release Carbamazepine (Equetro) for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005 (Issue 1205)
by the FDA, has been used for many
years as an alternative treatment for this indication.
1
CLINICAL ...
An extended-release formulation of carbamazepine, available since 1997 for treatment of epilepsy, has now been approved under a new name, Equetro, for acute mania and mixed episodes of bipolar disorder. Although the drug was effective in some patients for up to 6 months, it has not been approved for maintenance treatment. Carbamazepine has not been shown to be more effective than lithium or valproate, and it can cause serious adverse effects.
Intravenous Ibandronate (Boniva)
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006 (Issue 1241)
• A Nonprofit Publication
In the 1-year non-inferiority trial, 1358 postmenopausal
women with osteoporosis ...
Ibandronate (Boniva - Roche) is the first bisphosphonate approved by the FDA for intravenous (IV) treatment of osteoporosis in postmenopausal women. It is given as a bolus injection once every 3 months. Ibandronate is also available as an oral once-a-month 150-mg tablet and as a daily 2.5-mg tablet.
Telbivudine (Tyzeka) for Chronic Hepatitis B
The Medical Letter on Drugs and Therapeutics • Jan 29, 2007 (Issue 1253)
in the US.
DRUG DOSAGE
1
COST
2
Adefovir – Hepsera (Gilead) 10 mg once/d $675.90
Entecavir – Baraclude 0.5 mg ...
The FDA has approved the nucleoside analog telbivudine (Tyzeka - Novartis/Idenix) for treatment of patients ≥16 years old with active chronic hepatitis B virus (HBV) infection. It is the fourth oral drug marketed for this indication in the US.
Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures
The Medical Letter on Drugs and Therapeutics • Dec 03, 2007 (Issue 1275)
The American Heart Association has issued its revised
guidelines for prevention of infective endocarditis.
1 ...
The American Heart Association has issued its revised guidelines for prevention of infective endocarditis. Antimicrobial prophylaxis for dental procedures is now recommended only for patients at the highest risk of severe consequences from endocarditis who are undergoing the highest-risk procedures. Endocarditis prophylaxis is no longer recommended for gastrointestinal (GI) and genitourinary (GU) procedures. When these changes are implemented, the number of patients receiving antimicrobial prophylaxis to prevent endocarditis should decline sharply.
Certolizumab (Cimzia) for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008 (Issue 1297)
Cost
1
Adalimumab –
Humira (Abbott) 20, 40 mg pre- 40 mg SC $3,145.16
filled syringe q2 wks ...
The FDA has approved the marketing of certolizumab pegol (Cimzia - UCB), a tumor necrosis factor (TNF) blocker, for treatment of moderate to severe Crohn's disease refractory to conventional treatment. It is the third TNF blocker approved for this indication.
Ezogabine (Potiga) for Epilepsy
The Medical Letter on Drugs and Therapeutics • Aug 20, 2012 (Issue 1397)
. Ezogabine is available
in Europe as retigabine (Trobalt).1
DRUGS FOR PARTIAL SEIZURES — Partial
seizures ...
The FDA has approved ezogabine (ee-ZOE-ga-been;
Potiga – GSK/Valeant) for oral adjunctive treatment of
partial-onset seizures in adults. Ezogabine is available
in Europe as retigabine (Trobalt).
Colorectal Cancer Screening
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
(polyp) can prevent
cancer from developing.1
WHO SHOULD BE SCREENED — Routine screening for
colorectal ...
Most colorectal cancers arise from localized
adenomatous polyps in a process that may take
10 years or more. Early detection and removal of
a precancerous colonic lesion (polyp) can prevent
cancer from developing.
Deuruxolitinib (Leqselvi) for Severe Alopecia Areata
The Medical Letter on Drugs and Therapeutics • Oct 27, 2025 (Issue 1740)
alopecia areata: baricitinib (Olumiant) is approved for
use in adults,1 and ritlecitinib (Litfulo ...
The FDA has approved the oral Janus kinase (JAK)
inhibitor deuruxolitinib (Leqselvi – Sun) for treatment
of severe alopecia areata in adults. Two other oral
JAK inhibitors are approved for treatment of severe
alopecia areata: baricitinib (Olumiant) is approved for
use in adults, and ritlecitinib (Litfulo) is approved for
use in patients ≥12 years old.
Med Lett Drugs Ther. 2025 Oct 27;67(1740):174-6 doi:10.58347/tml.2025.1740b | Show Introduction Hide Introduction
Drugs for Anxiety Disorders
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
for those ≤7 years
old or ≥65 years old because of insufficient evidence.1
PHARMACOTHERAPY
Several drug ...
Anxiety disorders (generalized anxiety disorder,
panic disorder, social anxiety disorder, and various
phobias) are the most common form of psychiatric
illness. They can be treated effectively with cognitive
behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8 doi:10.58347/tml.2023.1682a | Show Introduction Hide Introduction
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
diabetes.1
Recent findings that some of the newer second-line
drugs for type 2 diabetes ...
...
